Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders on Launch of Jakafi and Lead Clinical Programs

  Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders on
  Launch of Jakafi and Lead Clinical Programs

  *$43.7 million of Jakafi^® (ruxolitinib) recognized as third-quarter U.S.
    net product revenue including $9.0 million of previously deferred revenue
  *Third quarter dispenses to patients increased 16 percent over second
    quarter
  *Ruxolitinib approved for use in the European Union

               Conference Call Scheduled Today at 8:30 a.m. ET

Business Wire

WILMINGTON, Del. -- November 01, 2012

Incyte Corporation (Nasdaq: INCY) today reported third-quarter 2012 financial
results, including revenue from its first commercial product, Jakafi^®
(ruxolitinib), which was approved by the U.S. Food & Drug Administration (FDA)
for the treatment of patients with intermediate or high-risk myelofibrosis
(MF) in November 2011. Novartis, the Company’s collaboration partner,
announced that Jakafi, marketed as Jakavi^® outside the United States,
received approval from the European Commission for the treatment of
disease-related splenomegaly or symptoms in adult patients with primary MF,
post-polycythemia vera MF or post-essential thrombocythemia MF. Jakafi/Jakavi
is the first medicine to receive FDA and European Commission approval to treat
patients with myelofibrosis and the first JAK inhibitor to be approved for any
indication.

“We’re encouraged by the underlying demand for Jakafi, and we are building a
strong foundation for long-term growth. With continued efforts to expand the
use of Jakafi among new and existing prescribers, extensive educational
efforts around the optimal use of Jakafi, and additional data being presented
at the upcoming American Society of Hematology annual meeting, we’re confident
that we will continue to see steady, consistent growth,” stated Paul A.
Friedman, M.D., Incyte’s President and Chief Executive Officer.

2012 Third-Quarter Financial Results

Product Revenues

For the quarter and nine months ended September 30, 2012, net product revenues
of Jakafi were $43.7 million and $92.7 million, respectively.

As expected, in the third quarter, the Company transitioned to the sell-in
revenue recognition method from the sell-through method. Under the sell-in
method, revenue is recognized when product is received by the specialty
pharmacy, whereas under the sell-through method, revenue is recognized when
the specialty pharmacy sends product to the patient, which reflects clinical
demand. As a result, the $43.7 million of net product revenues for the third
quarter of 2012 included $9.0 million of previously deferred revenue,
representing product held by the specialty pharmacies at June 30, 2012.

For comparative purposes, the following table presents the Company’s net
product revenues as recognized for the three months ended March 31, 2012, and
June 30, 2012, under the sell-through method, and as if the Company were still
using the sell-through method for the three months ended September 30, 2012,
which reflects a 16 percent increase in dispenses to patients from the second
quarter to the third quarter:

                                                      
                       Three Months     Three Months     Three Months Ended
Sell-Through Method     Ended             Ended
                       March 31, 2012   June 30, 2012    September 30, 2012
Product revenues, net
                       $ 19.3           $ 29.7           $ 34.5*
(in millions)
                                                            

* The $34.5 million excludes $9.0 million of previously deferred revenue and
$0.2 million of gross-to-net adjustments and changes in inventory levels at
the specialty pharmacies during the quarter.

2012 Guidance Update

The Company is updating its 2012 guidance and now anticipates that Jakafi net
product revenues will be in the range of $130 million to $135 million, a
change from the previous range of $120 million to $135 million.

Total Revenues

Total revenues for the quarter and nine months ended September 30, 2012, were
$60.5 million and $183.2 million, respectively, as compared to $16.8 million
and $65.6 million, respectively, for the same periods in 2011. Included in
total revenues for the quarter and nine months ended September 30, 2012, were
net product revenues of $43.7 million and $92.7 million, respectively.

Included in total revenues for the nine months ended September 30, 2012, was a
$40 million European Union regulatory milestone payment received from Novartis
related to Jakavi. Included in total revenues for the nine months ended
September 30, 2011, was a $15 million milestone payment received from Novartis
related to INCB28060.

Net Loss

Net loss for the quarter ended September 30, 2012, was $21.7 million, or $0.17
per basic and diluted share, as compared to $53.1 million, or $0.42 per basic
and diluted share, for the same period in 2011. Net loss for the nine months
ended September 30, 2012, was $63.1 million, or $0.49 per basic and diluted
share, as compared to a net loss of $131.5 million, or $1.05 per basic and
diluted share, for the same period in 2011. Included in net loss for the nine
months ended September 30, 2012, was a $40 million European Union regulatory
milestone payment received from Novartis related to Jakavi. Included in net
loss for the nine months ended September 30, 2011, was a $15 million milestone
payment received from Novartis related to INCB28060.

Also included in net loss for the quarter and nine months ended September 30,
2012, were $9.5 million and $29.4 million, respectively, of non-cash expenses
related to the impact of expensing employee stock options, compared to $7.4
million and $21.5 million, respectively, for the same periods in 2011.

Operating Expenses

Research and development expenses for the quarter and nine months ended
September 30, 2012, were $50.1 million and $150.6 million, respectively, as
compared to $44.6 million and $126.8 million, respectively, for the same
periods in 2011. Included in research and development expenses for the quarter
and nine months ended September 30, 2012, were non-cash expenses of $6.4
million and $19.6 million, respectively, related to the impact of expensing
employee stock options, as compared to $4.8 million and $14.0 million,
respectively, for the same periods in 2011.

The increases in research and development expenses for the quarter and nine
months ended September 30, 2012, compared to the prior year periods were
primarily a result of increased clinical development costs related to the
advancement of the Company's pipeline and increased non-cash employee stock
option expense. The Company expects its research and development expenses to
vary from period to period, mainly due to the timing of its clinical
development activities.

Selling, general and administrative expenses for the quarter and nine months
ended September 30, 2012, were $20.5 million and $61.6 million, respectively,
as compared to $14.3 million and $37.1 million, respectively, for the same
periods in 2011. Included in selling, general and administrative expenses for
the quarter and nine months ended September 30, 2012, were non-cash expenses
of $3.1 million and $9.8 million, respectively, related to the impact of
expensing employee stock options, as compared to $2.6 million and $7.5
million, respectively, for the same periods in 2011.

Increased selling, general and administrative expenses for the quarter and
nine months ended September 30, 2012, compared to the prior year periods
reflected the additional costs related to the Company's sales force and the
commercialization efforts for the launch of Jakafi.

Interest Expense

Interest expense for the quarter and nine months ended September 30, 2012, was
$11.6 million and $34.3 million, respectively, as compared to $11.0 million
and $32.7 million, respectively, for the comparable periods in 2011. Included
in interest expense for the quarter and nine months ended September 30, 2012,
were $6.8 million and $20.0 million, respectively, of non-cash charges to
amortize the discount on the Company's 4.75% Convertible Senior Notes due
2015, as compared to $6.3 million and $18.4 million, respectively, for the
same periods in 2011.

Cash Position

As of September 30, 2012, cash, cash equivalents and marketable securities
totaled $243.6 million compared to $277.6 million as of December 31, 2011.
These amounts exclude $9.5 million and $19.0 million, as of September 30,
2012, and December 31, 2011, respectively, of restricted cash and investments
held in an escrow account reserved for interest payments through October 2012
on the 4.75% Convertible Senior Notes.

Recent Clinical Highlights

Jakafi^® (ruxolitinib) - a JAK1 and JAK2 Inhibitor

  *The use of Jakafi to treat patients with intermediate or high-risk
    myelofibrosis (MF) is further supported by presentations to be made at the
    American Society of Hematology annual meeting in December, including
    updates from COMFORT-I and COMFORT-II.

       *Verstovsek, S, et al. Long-Term Outcome of Ruxolitinib Treatment in
         Patients with Myelofibrosis: Durable Reductions in Spleen Volume,
         Improvements in Quality of Life, and Overall Survival Advantage in
         Comfort-I. Dec. 10, 2012, at 6:30 p.m.
       *Cervantes, F, et al. Long-Term Safety, Efficacy, and Survival
         Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with
         Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF).
         Dec. 10, 2012, at 6:45 p.m.
       *Vannucchi, A, et al. Reductions in JAK2 V617F Allele Burden with
         Ruxolitinib Treatment in Comfort-II, A Phase 3 Study Comparing the
         Efficacy and Safety of Ruxolitinib with Best Available Therapy (BAT).
         Dec. 10, 2012, at 7 p.m.

  *Two Phase III clinical trials (RESPONSE and RELIEF), in partnership with
    Novartis, are underway to evaluate ruxolitinib in patients with
    polycythemia vera (PV) with results expected to be part of a supplemental
    new drug application submission in 2014. The FDA has granted fast track
    designation for PV, specifically for the treatment of patients with PV who
    are resistant to or intolerant of hydroxyurea.
  *A randomized Phase II trial of ruxolitinib in combination with
    capecitabine is actively recruiting patients with recurrent or treatment
    refractory metastatic pancreatic cancer (the RECAP trial). The RECAP trial
    is designed to enroll approximately 130 patients by late 2012, with final
    results expected in the second half of 2013.
  *Multiple investigator-sponsored trials evaluating ruxolitinib are ongoing,
    including two Phase I/II trials in adults with advanced hematologic
    malignancies (acute myeloid leukemia, acute lymphocytic leukemia,
    myelodysplastic syndrome and chronic myelogenous leukemia) and relapsed or
    refractory acute leukemia; a Phase I/II trial in children with hematologic
    malignancies and solid tumors; and a Phase II trial in patients with
    lymphoma. In addition, the first of several planned investigator-sponsored
    Phase II trials to evaluate ruxolitinib in treating patients with breast
    cancer was recently initiated.

Baricitinib, formerly known as LY3009104 (INCB28050) - a JAK1 and JAK2
Inhibitor

  *Data from the six-month Phase IIb trial of baricitinib in patients with
    rheumatoid arthritis, conducted by our collaboration partner Eli Lilly and
    Company, will be presented at the American College of Rheumatology Annual
    Scientific Meeting in November 2012.
  *A Phase III trial of baricitinib in patients with rheumatoid arthritis,
    conducted by Lilly, began screening patients in October 2012.
  *A Phase IIb trial in patients with moderate to severe psoriasis, conducted
    by Lilly, is ongoing with primary endpoint results expected in 2013.
  *A Phase II trial in patients with diabetic nephropathy, conducted by
    Lilly, was initiated in August 2012, and results are expected in 2014.

INCB28060 (also known as INC280) – a c-MET Inhibitor

  *The initial Phase I trial in patients with solid tumors is nearing
    completion. This compound is licensed to Novartis as part of the
    Incyte-Novartis collaboration, and further development will be conducted
    by Novartis.

INCB24360 – an Indoleamine Dioxygenase-1 (IDO1) Inhibitor

  *INCB24360 is currently in Phase I/II clinical development for metastatic
    melanoma in combination with ipilimumab and as monotherapy for ovarian
    cancer.

Early-Stage Development and Discovery Programs

  *Several early development and discovery programs in oncology and
    inflammation are also ongoing.

Conference Call Information

Incyte will hold its third-quarter 2012 financial results conference call this
morning at 8:30 a.m. ET. To access the conference call, please dial
877-407-8037 for domestic callers or 201-689-8037 for international callers.
When prompted, provide the conference identification number, 401502.

If you are unable to participate, a replay of the conference call will be
available for 30 days. The replay dial-in number for the United States is
877-660-6853 and the dial-in number for international callers is 201-612-7415.
To access the replay you will need the conference identification number,
401502.

The conference call will also be webcast live and can be accessed at
www.incyte.com under Investor Relations – Events and Webcasts.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company
focused on the discovery, development and commercialization of proprietary
small molecule drugs for oncology and inflammation. For additional information
on Incyte, please visit the Company’s website at www.incyte.com.

About Jakafi

Jakafi is a prescription medicine used to treat people with intermediate or
high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF
and post–essential thrombocythemia MF.

Important Safety Information

  *Treatment with Jakafi can cause hematologic adverse reactions, including
    thrombocytopenia, anemia and neutropenia, which are each dose-related
    effects, with the most frequent being thrombocytopenia and anemia. A
    complete blood count must be performed before initiating therapy with
    Jakafi. Complete blood counts should be monitored as clinically indicated
    and dosing adjusted as required. The three most frequent non-hematologic
    adverse reactions were bruising, dizziness and headache
  *Patients with platelet counts <200 × 10^9/L at the start of therapy are
    more likely to develop thrombocytopenia during treatment. Thrombocytopenia
    was generally reversible and was usually managed by reducing the dose or
    temporarily withholding Jakafi. If clinically indicated, platelet
    transfusions may be administered
  *Patients developing anemia may require blood transfusions. Dose
    modifications of Jakafi for patients developing anemia may also be
    considered
  *Neutropenia (ANC <0.5 × 10^9/L) was generally reversible and was managed
    by temporarily withholding Jakafi
  *Patients should be assessed for the risk of developing serious bacterial,
    mycobacterial, fungal and viral infections. Active serious infections
    should have resolved before starting Jakafi. Physicians should carefully
    observe patients receiving Jakafi for signs and symptoms of infection
    (including herpes zoster) and initiate appropriate treatment promptly
  *A dose modification is recommended when administering Jakafi with strong
    CYP3A4 inhibitors or in patients with renal or hepatic impairment [see
    Dosage and Administration]. Patients should be closely monitored and the
    dose titrated based on safety and efficacy
  *There are no adequate and well-controlled studies of Jakafi in pregnant
    women. Use of Jakafi during pregnancy is not recommended and should only
    be used if the potential benefit justifies the potential risk to the fetus
  *Women taking Jakafi should not breast-feed. Discontinue nursing or
    discontinue the drug, taking into account the importance of the drug to
    the mother

For Full Prescribing Information for Jakafi, visit www.Jakafi.com.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth
in this press release, including without limitation statements regarding our
plans and expectations with respect to Jakafi (ruxolitinib), including the
potential efficacy and therapeutic and commercial value of Jakafi, our
expectation regarding continued steady, consistent growth, our expectation
that results from the RESPONSE and RELIEF trials are expected to be part of a
sNDA submission in 2014, our expectation that the RECAP trial will enroll
approximately 130 patients by late 2012 with final results expected in the
second half of 2013, our expectation that results from the trials conducted by
our collaboration partner Eli Lilly and Company evaluating baricitinib in
patients with moderate to severe psoriasis and diabetic nephropathy will be
available in 2013 and 2014, respectively, our expectation that the initial
Phase I trial evaluating INCB28060 is nearing completion, updated financial
guidance about expected net product revenues, and expectations regarding
variations in research and development expenses, contain predictions,
estimates and other forward-looking statements.

These forward-looking statements are based on Incyte’s current expectations
and subject to risks and uncertainties that may cause actual results to differ
materially, including unanticipated developments in and risks related to the
efficacy or safety of Jakafi, the acceptance of Jakafi in the marketplace,
risks related to market competition, the results of further research and
development, risks and uncertainties associated with sales, marketing and
distribution requirements, risks that results of clinical trials may be
unsuccessful or insufficient to meet applicable regulatory standards, the
ability to enroll sufficient numbers of subjects in clinical trials, other
market or economic factors and technological advances, unanticipated delays,
the ability of Incyte to compete against parties with greater financial or
other resources, risks associated with Incyte's dependence on its
relationships with its collaboration partners, and other risks detailed from
time to time in Incyte’s reports filed with the Securities and Exchange
Commission, including our Form 10-Q for the quarter ended June 30, 2012.

Incyte disclaims any intent or obligation to update these forward-looking
statements.


INCYTE CORPORATION
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
                                                   
                            Three Months Ended        Nine Months Ended
                            September 30,             September 30,
                             2012       2011        2012       2011
Revenues:
Product revenues, net       $ 43,695     $ -          $ 92,700     $ -
Contract revenues             16,737       16,737       90,211       65,211
Other revenues               60          45          302         354
                                                                   
Total revenues               60,492      16,782      183,213     65,565
                                                                   
Costs and expenses:
Cost of product revenues      31           -            58           -
Research and development      50,079       44,604       150,627      126,830
Selling, general and          20,520       14,282       61,634       37,067
administrative
Other expenses               -           -           -           712
                                                                   
Total costs and expenses     70,630      58,886      212,319     164,609
                                                                   
Loss from operations          (10,138)     (42,104)     (29,106)     (99,044)
Interest and other            27           45           393          249
income, net
Interest expense             (11,573)    (11,019)    (34,293)    (32,666)
                                                                   
Loss before income taxes      (21,684)     (53,078)     (63,006)     (131,461)
                                                                   
Provision for income         26          -           93          -
taxes
                                                                   
Net loss                    $ (21,710)   $ (53,078)   $ (63,099)   $ (131,461)
                                                                   
Basic and diluted net       $ (0.17)     $ (0.42)     $ (0.49)     $ (1.05)
loss per share
                                                                   
Shares used in computing
basic and diluted net         130,851      126,260      129,093      125,019
loss per share
                                                                   


INCYTE CORPORATION
Condensed Consolidated Balance Sheet Data
(in thousands)
                                                               
                                                  September 30,   December 31,
                                                  2012            2011
                                                                  
Cash, cash equivalents, and short-term            $  243,599      $  277,594
marketable securities
Accounts receivable, net                             16,540          6,415
Deferred revenue – Product revenues                  -               2,332
Total assets                                         296,535         328,962
Convertible senior notes                             315,874         298,193
Convertible subordinated notes                       18,725          17,960
Total stockholders’ deficit                          (219,950)       (227,077)
                                                                  

Contact:

Incyte Corporation
Pamela M. Murphy
Vice President, Investor Relations & Corporate Communications
302-498-6944
 
Press spacebar to pause and continue. Press esc to stop.